SEARCH

SEARCH BY CITATION

References

  • 1
    Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 41722.
  • 2
    Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10: 2506.
  • 3
    Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997; 32(12): 124755.
  • 4
    Buchman AL. Bones and Crohn's: problems and solutions. Inflamm Bowel Dis 1999; 5(3): 21227.
  • 5
    Compston JE. Review article: osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmacol Ther 1995; 9: 23750.
  • 6
    De Vos M, De Keyser F, Mielants H, Cuvelier C, Veys E. Review article: bone and joint diseases in inflammatory bowel disease. Aliment Pharmacol Ther 1998; 12(5): 397404.
  • 7
    Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94(4): 87883.
    Direct Link:
  • 8
    Bernstein CN, Leslie W, LeBoff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124(3): 795841.
  • 9
    Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 22833.
  • 10
    Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992; 37: 1396403.
  • 11
    Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93(9): 148390.
    Direct Link:
  • 12
    Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995; 5: 15660.
  • 13
    Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998; 4(4): 26875.
  • 14
    Robinson RJ, Al Azzawi F, Iqbal SJ, Abrams K, Mayberry JF. The relation of hand skin-fold thickness to bone mineral density in patients with Crohn's disease. Eur J Gastroenterol Hepatol 1997; 9: 9459.
  • 15
    Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 3139.
  • 16
    Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 716.
  • 17
    Abitbol V, Roux C, Guillemant S, et al. Bone assessment in patients with ileal pouch-anal anastomosis for inflammatory bowel disease. Br J Surg 1997; 84: 15514.
  • 18
    Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease. A case–control cross-sectional study of 113 patients. Am J Gastroenterol 1999; 94(3): 8248.
    Direct Link:
  • 19
    Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJM. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000; 119(5): 12038.
  • 20
    Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol 1999; 34(7): 696702.
  • 21
    Silvennoinen J, Lamberg-Allardt C, Karkkainen M, Niemela S, Lehtola J. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med 1996; 240: 28592.
  • 22
    Staun M, Jarnum S. Measurement of the 10,000-molecular weight calcium-binding protein in small-intestinal biopsy specimens from patients with malabsorption syndromes. Scand J Gastroenterol 1988; 23(7): 82732.
  • 23
    Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46(2): 17681.
  • 24
    Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002; 156(1): 110.
  • 25
    Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease — a population-based cohort study. Ann Intern Med 2000; 133(10): 7959.
  • 26
    Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ III. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002; 123(2): 46875.
  • 27
    Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999; 149(10): 91624.
  • 28
    Van Staa T-P, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk fracture. Gastroenterology 2003; 125: 15917.
  • 29
    Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002; 51(5): 6548.
  • 30
    Fujiwara S, Mizuno S, Ochi Y, et al. The incidence of thoracic vertebral fractures in a Japanese population, Hiroshima and Nagasaki, 1958–86. J Clin Epidemiol 1991; 44(10): 100714.
  • 31
    Ismail AA, Cooper C, Felsenberg D, et al. Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int 1999; 9(3): 20613.
  • 32
    Jackson SA, Tenenhouse A, Robertson L, et al. Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 2000; 11(8): 6807.
  • 33
    Szulc P, Munoz F, Marchand F, Delmas PD. Semiquantitative evaluation of prevalent vertebral deformities in men and their relationship with osteoporosis: the MINOS study. Osteoporos Int 2001; 12(4): 30210.
  • 34
    Gehlbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR. Recognition of vertebral fracture in a clinical setting. Osteoporos Int 2000; 11(7): 57782.
  • 35
    Espallargues M, Sampietro-Colom L, Estrada MD, et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporos Int 2001; 12(10): 81122.
  • 36
    Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001; 12(7): 51928.
  • 37
    Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15(4): 72139.
  • 38
    Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114(11): 91923.
  • 39
    Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23(4): 5708.
  • 40
    NIH Consensus Conference on Optimal Calcium Intake. NIH Consensus Development Panel on Optimal Calcium Intake. J Am Med Assoc 1994; 272(24): 19428.
  • 41
    NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy, March 7–29, 2000. Highlights of the conference. South Med J 2001; 94(6): 56973.
  • 42
    Sentipal JM, Wardlaw GM, Mahan J, Matkovic V. Influence of calcium intake and growth indexes on vertebral bone mineral density in young females. Am J Clin Nutr 1991; 54(2): 4258.
  • 43
    Corazza GR, Benati G, Di Sario A, et al. Lactose intolerance and bone mass in postmenopausal Italian women. Br J Nutr 1995; 73(3): 47987.
  • 44
    Infante D, Tormo R. Risk of inadequate bone mineralization in diseases involving long-term suppression of dairy products. J Pediatr Gastroenterol Nutr 2000; 30(3): 3103.
  • 45
    Honkanen R, Kroger H, Alhava E, Turpeinen P, Tuppurainen M, Saarikoski S. Lactose intolerance associated with fractures of weight-bearing bones in Finnish women aged 38–57 years. Bone 1997; 21(6): 4737.
  • 46
    Di Stefano M, Veneto G, Malservisi S, et al. Lactose malabsorption and intolerance and peak bone mass. Gastroenterology 2002; 122(7): 17939.
  • 47
    Bernstein CN, Leslie WD, Taback SP. Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol 2003; 98(5): 1094100.
    Direct Link:
  • 48
    Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol 2003; 98(11): 246873.
    Direct Link:
  • 49
    Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002; 8(2): 8792.
  • 50
    Reid IR. Relationships among body mass, its components, and bone. Bone 2002; 31(5): 54755.
  • 51
    Jahnsen J, Falch JA, Mowinckel P, Aadland E. Body composition in patients with inflammatory bowel disease: a population-based study. Am J Gastroenterol 2003; 98(7): 155662.
    Direct Link:
  • 52
    Golden NH, Lanzkowsky L, Schebendach J, Palestro CJ, Jacobson MS, Shenker IR. The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J Pediatr Adolesc Gynecol 2002; 15(3): 13543.
  • 53
    Mehler PS. Osteoporosis in anorexia nervosa: prevention and treatment. Int J Eat Disord 2003; 33(2): 11326.
  • 54
    Gordon CM, Grace E, Emans SJ, et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab 2002; 87(11): 493541.
  • 55
    De Jong DJ, Corstens FH, Mannaerts L, Van Rossum LG, Naber AH. Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease? Am J Gastroenterol 2002; 97(8): 20115.
  • 56
    Bernstein CN, Blanchard JF, Metge C, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003; 98(8): 1797801.
    Direct Link:
  • 57
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15(6): 9931000.
  • 58
    Van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003; 18(5): 9138.
  • 59
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39(12): 13839.
  • 60
    Dear KL, Compston JE, Hunter JO. Treatments for Crohn's disease that minimise steroid doses are associated with a reduced risk of osteoporosis. Clin Nutr 2001; 20(6): 5416.
  • 61
    Kuisma J, Luukkonen P, Jarvinen H, Kahri A, Farkkila M. Risk of osteopenia after proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2002; 37(2): 1716.
  • 62
    Varghese S, Wyzga N, Griffiths AM, Sylvester FA. Effects of serum from children with newly diagnosed Crohn disease on primary cultures of rat osteoblasts. J Pediatr Gastroenterol Nutr 2002; 35(5): 6418.
  • 63
    Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327(23): 163742.
  • 64
    Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337(10): 6706.
  • 65
    Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002; 37(2): 1929.
  • 66
    Blumsohn A, Naylor KE, Timm W, Eagleton AC, Hannon RA, Eastell R. Absence of marked seasonal change in bone turnover: a longitudinal and multicenter cross-sectional study. J Bone Miner Res 2003; 18(7): 127481.
  • 67
    Rucker D, Allan JA, Fick GH, Hanley DA. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ 2002; 166(12): 151724.
  • 68
    Weber AM, Ziegler C, Belinson JL, Mitchinson AR, Widrich T, Fazio V. Gynecologic history of women with inflammatory bowel disease. Obstet Gynecol 1995; 86(5): 8437.
  • 69
    Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993; 34: 15436.
  • 70
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288(3): 32133.
  • 71
    Robinson RJ, Iqbal SJ, Al Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther 1998; 12(1): 215.
  • 72
    Szathmari M, Vasarhelyi B, Treszl A, Tulassay T, Tulassay Z. Association of dehydroepiandrosterone sulfate and testosterone deficiency with bone turnover in men with inflammatory bowel disease. Int J Colorectal Dis 2002; 17(2): 636.
  • 73
    Straub RH, Vogl D, Gross V, Lang B, Scholmerich J, Andus T. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol 1998; 93(11): 2197202.
    Direct Link:
  • 74
    De La Torre B, Hedman M, Befrits R. Blood and tissue dehydroepiandrosterone sulphate levels and their relationship to chronic inflammatory bowel disease. Clin Exp Rheumatol 1998; 16(5): 57982.
  • 75
    Gennari L, Merlotti D, Martini G, et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003; 88(11): 532733.
  • 76
    Khosla S, Melton LJ III, Riggs BL. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab 2002; 87(4): 144350.
  • 77
    Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ III, Riggs BL. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002; 17(1): 1728.
  • 78
    Van PI, Goemaere S, Kaufman JM. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 2003; 88(7): 307581.
  • 79
    Cheng ZN, Zhou HH. Contribution of genetic variations in estradiol biosynthesis and metabolism enzymes to osteoporosis. Acta Pharmacol Sin 2000; 21(7): 58790.
  • 80
    Ralston SH. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 2002; 87(6): 24606.
  • 81
    Recker RR, Deng HW. Role of genetics in osteoporosis. Endocrine 2002; 17(1): 5566.
  • 82
    Peacock M, Turner CH, Econs MJ, Foroud T. Genetics of osteoporosis. Endocr Rev 2002; 23(3): 30326.
  • 83
    Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142(12): 50505.
  • 84
    Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res 2002; 17(7): 124555.
  • 85
    Nemetz A, Toth M, Garcia-Gonzalez MA, et al. Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut 2001; 49(5): 6449.
  • 86
    Nemetz A, Nosti-Escanilla MP, Molnar T, et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 1999; 49(6): 52731.
  • 87
    Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332(5): 30511.
  • 88
    Kusugami K, Fukatsu A, Tanimoto M, et al. Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Dig Dis Sci 1995; 40(5): 94959.
  • 89
    Mahida YR, Kurlac L, Gallagher A, Hawkey CJ. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1991; 32(12): 15314.
  • 90
    Schulte C, Goebell H, Roher HD, Schulte KM. Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease. Dig Dis Sci 2001; 46(11): 25218.
  • 91
    Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 2003; 32(1): 13557, vii.
  • 92
    Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119(3): 63946.
  • 93
    Von Tirpitz C, Klaus J, Bruckel J, et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000; 12(1): 1924.
  • 94
    Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10: 77786.
  • 95
    Von Tirpitz C, Klaus J, Steinkamp M, et al. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003; 17(6): 80716.
  • 96
    Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002; 87(10): 44705.
  • 97
    Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14(4): 51827.
  • 98
    Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112(4): 2819.
  • 99
    Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167(10 Suppl.): S134.
  • 100
    Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003; 14(1): 7781.
  • 101
    Turner CH. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002; 13(2): 97104.
  • 102
    Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 143441.
  • 103
    Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 2003; 19(2): 395414.
  • 104
    Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349(13): 120715.
  • 105
    Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359(9321): 192936.